Evidence map›Paper›PMID 34176244›Full record

ArticlePharmacology research & perspectives2021

Cannabidiol-mediated RISK PI3K/AKT and MAPK/ERK pathways decreasing reperfusion myocardial damage.

Antonio Franco-Vadillo, Mireille Toledo-Blass, Zeltzin Rivera-Herrera, Gustavo Guevara-Balcazar, Oscar Orihuela-Rodriguez, Jose A Morales-Carmona, Alexandre Kormanovski-Kovzova, Pedro Lopez-Sanchez, Ivan Rubio-Gayosso, Maria Del Carmen Castillo-Hernandez

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Antonio Franco-VadilloSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0002-2904-1709
Mireille Toledo-BlassSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0003-3789-0898
Zeltzin Rivera-HerreraSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0003-2472-1032
Gustavo Guevara-BalcazarSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0002-0050-4765
Oscar Orihuela-RodriguezHospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico.ORCID 0000-0001-7148-5533
Jose A Morales-CarmonaSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0003-0150-1352
Alexandre Kormanovski-KovzovaSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0001-8731-0527
Pedro Lopez-SanchezSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.
Ivan Rubio-GayossoSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0001-8315-8572
Maria Del Carmen Castillo-HernandezSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico, Mexico.ORCID 0000-0003-1192-6776
Instituto Politécnico Nacional · MXMexican Social Security Institute · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia continues to be the first cause of morbimortality in the world; the definitive treatment is reperfusion; however, this action causes additional damage to ischemic myocardial tissue; this forces to seek therapies of cardioprotection to reduce this additional damage. There are many cardioprotective agents; within these, cannabinoids have shown to have beneficial effects, mainly cannabidiol (CBD). CBD is a non psychoactive cannabinoid. To evaluate the effect in experimental models of CBD in myocardial ischemia reperfusion in rats, twelve-week-old male rats have been used. The animals were divides in 3 groups: control(C), ischemia reperfusion (IR) and CBD pretreatment (1/day/5mg/kg /10days). Langendorff organ isolate studies were performed, and the area of infarction was assessed with triphenyl tetrazolium, in addition to molecular analysis of AT1 and AT2 receptors and Akt and Erk proteins and their phosphorylated forms related to RISK pathways. It was observed that there is an improvement with the use of CBD increasing inotropism and cardiac lusitropism, improving considerably the cardiovascular functionality. These could be related to the reduction of the area of infarction and activation of the AT2 receptor and the RISK pathway with absence of activation of the AT2 receptor (these could relate the reduction of the infarct area and the restoration of cardiovascular function with the activation of the AT2 receptor and the RISK pathway with the absence of activation of the AT2 receptor). The use of cannabinoids was shown to have beneficial effects when used as a treatment for myocardial reperfusion damage.

Indexed as

AnimalsCannabidiolCardiotonic AgentsHeartHemodynamicsIn Vitro TechniquesMaleMAP Kinase Signaling SystemMyocardial Reperfusion InjuryPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsRats, WistarReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2Ventricular Function, LeftCannabidiolCardiotonic AgentsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptor, Angiotensin, Type 1Receptor, Angiotensin, Type 2AT1 receptorAT2 receptorcannabidiolMAPK/ERKmyocardial damage by reperfusionPI3K/AKTRISK pathways

Identifiers

PMID34176244
PMCPMC8236079
OpenAlexW3176152507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.